Abstract: The present invention relates to dust-free preparations dispersible in cold water. These preparations consist of particles comprising water-insoluble or only sparingly water-soluble active substance(s), said particles being coated with one or more layers, the outermost layer comprising as principal component one or more hydrophobic powdering agents on which at least one dispersant is absorbed. The invention also relates to a process for producing these particles and to the use thereof in food supplements, foodstuffs, animal feeds, personal-care products, and medicaments.

Abstract: Pesticidal compositions for improving physical characteristics of pesticide formulations which comprise natural pesticidal oil active ingredients are disclosed. One such composition comprises a pesticidal natural oil active ingredient, a surfactant to disperse the active ingredient in a water emulsion, a polymeric pour point depressant effective to reduce a pour point temperature of the pesticidal natural oil active ingredient and a hydrocarbon solvent. Methods for providing pesticidal compositions and application to control one or more pests are also disclosed.

Abstract: Disclosed are a pharmaceutical composition for treatment of attention deficit hyperactivity disorder and a food composition for alleviation of attention deficit hyperactivity disorder, each of which contains as an active ingredient a mixture extract of Longan Arillus, Salviae Miltiorrhizae Radix, Gastrodiae Rhizoma, and Liriopis seu Ophiopogonis Tuber, wherein the compositions containing as an active ingredient a mixture extract of Longan Arillus, Salviae Miltiorrhizae Radix, Gastrodiae Rhizoma, and Liriopis seu Ophiopogonis Tuber of the present disclosure inhibits the hyperactivity of glutamate receptors, which is known to be a cause of attention deficit hyperactivity disorder, alleviates clinical symptoms (attention decrease and hyperactivity) of child patients, and shows an improvement effect in fMRI examination results, and thus can be advantageously used as a medicine for attention deficit hyperactivity disorder or a food for alleviation of attention deficit hyperactivity disorder.

Abstract: An anhydrous personal care composition, comprising: (a) 45 to 60 weight % of at least one ester, selected from (i) triglycerides, (ii) diglycerides, (iii) monoglycerides, (iv) monoesters of diols, and (v) diesters of diols; (b) a first wax having a melting point of from 35° C. to 72° C. present in an amount of 5 to 25 weight %; (c) a second wax having a melting point of 73 to 90° C. present in an amount of 0.5 to 15 weight %; and (d) at least one plant oil having a saponification value of from 150 to 275 mg KOH/g present in an amount of 5 to 35 weight.

Abstract: Provided herein are gastroretentive dosage forms (GRDFs) for extended retention in a human stomach, comprising a body comprising at least two arms, the body configured to transform between a collapsed configuration for ingestion, an expanded configuration for retention within the stomach and a disassembled configuration wherein after a predetermined time period has elapsed, the GRDF disassembles into at least two parts such that each of the disassembled parts of the GRDF is sized for exiting the stomach; and, an erodible insert comprising a therapeutic agent, a diagnostic agent, an electronical device, or a combination thereof.

Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

Abstract: Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

Abstract: Disclosed herein are compositions comprising insoluble alpha-glucan particles having a high degree of crystallinity and small particle size. For example, the alpha-glucan particles can have a degree of crystallinity of at least about 0.65, and/or an average size of less than a micron. At least 50% of the glycosidic linkages of the insoluble alpha-glucan in the disclosed particles are alpha-1,3 glycosidic linkages. Further disclosed are methods of producing insoluble alpha-glucan particles, as well as their use in various applications and products.

Abstract: A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.

Abstract: The present application provides methods of treating a CNS disorder (such as glioblastoma and epilepsy) in an individual, comprising systemically (e.g., intravenously or subcutaneously) administering to the individual an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, optionally further comprising administering a second agent (such as an anti-VEGF antibody, a proteasome inhibitor, or an alkylating agent).

Abstract: Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

Abstract: The present invention provides long-acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of Cariprazine or salts thereof, in a depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot compositions are preferably in the form of in-situ implants suitable for subcutaneous or intramuscular administration and provide prolonged release of the Cariprazine active ingredient and/or its metabolites desmethyl Cariprazine (DCAR) and didesmethyl Cariprazine (DDCAR) for a period of at least 4 weeks following a single administration. The present invention further provides methods of use of the depot compositions for the treatment of schizophrenia, major depressive disorder, and bipolar disorder.

Abstract: Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

Abstract: Nanogels and methods of synthesizing and using these nanogels are provided. The nanogels are formed by mixing a building block (e.g., polymer), crosslinker, preferably a target (e.g., biomedical compound or molecule), and a solvent in a multi-inlet vortex mixer, so as to cause the polymer and crosslinker to react and form a chemically crosslinked polymer network. In embodiments including a target, the target will be interspersed in and among that network and can be physically embedded and/or chemically bound therein.

Abstract: Disclosed herein are triglyceride based formulations, compositions, and methods for the treatment of otic diseases and conditions. Such triglyceride based formulations and compositions are derived from long-chain triglycerides and allow for the delivery of a variety of therapeutic agents to the outer, middle, and/or inner ear.

Abstract: The invention relates, generally, to porous absorbent materials which are suitable for packing antrums or other cavities of the human or animal body. More particularly, it relates to hydrophilic biodegradable foams, which may be used e.g. in the form of a plug or tampon, for instance for controlling bleeding, wound closure, prevent tissue adhesion and/or support tissue regeneration. The invention provides an absorbent foam, suitable for packing antrums or other cavities of the human or animal body, comprising a biodegradable synthetic polymer, which polymer preferably comprises —C(O)—O—groups in the backbone of the polymer, for instance polyurethane and/or polyester units combined with polyethers.

Abstract: The present specification discloses a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine in combination with one or more quaternary compounds or silicon quaternary compounds, one or more guanide-containing compounds, one or more alcohols, one or more metallic particles, one or more metal salts, or any combination thereof. The present specification further discloses a kit comprising, consisting essentially of, or consisting of a one or more containers including a composition disclosed herein or components which make up such compositions as well as methods and uses for such compositions and kits.

Abstract: Embodiments of the present invention provide a method of treating a stricture in a nonvascular body lumen such as urethral strictures, benign prostatic hyperplasia (BPH) strictures, ureteral strictures, esophageal strictures, sinus strictures, and biliary tract strictures. Embodiments of the present invention provide a method for treating at least one of benign prostatic hyperplasia (BPH), prostate cancer, asthma, and chronic obstructive pulmonary disease (COPD). The method can include delivering, for example, via drug coated balloon catheters, anti-inflammatory and anti-proliferative drugs (e.g., rapamycin, paclitaxel, and their analogues) and one or more additives.

Abstract: The present invention relates to new peptides comprising an amino acid sequence LL-[X]n-LL, wherein X is selected from R, L and W, and n=10 to 12, and wherein [X]n comprises 4 R, 4 L and between 2 and 4 W, that may be used as cell-penetrating peptides. The present invention also relates to nanoparticles comprising a peptide of the invention and a cargo molecule and uses thereof.

Abstract: Hydrogels are blended with water to produce a hydrogel solution. Viscosity of the hydrogel solution is controlled by adjusting the ratio of hydrogel to water and/or by adjusting the blending conditions. The hydrogel solutions may be used to modify the rheology of agricultural compositions. The hydrogel may include lactose, which may be provided by a milk permeate waste stream from the dairy or food processing industry.